Car T-Cell, an Issue of Hematology/Oncology Clinics of North America

Volume 37-6
Herausgeber: Jacobson, Caron A; Shah, Parth S

• Gebundenes Buch

Produktbeschreibung

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). * Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more.  * Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice.  * Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. 

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Health Sciences
• Seitenzahl: 240
• Erscheinungstermin: 13. Oktober 2023
• Englisch
• Abmessung: 229mm x 152mm
• Gewicht: 390g
• ISBN-13: 9780443183003
• ISBN-10: 0443183007
• Artikelnr.: 68211365

Inhaltsangabe

The Current State of Chimeric Antigen Receptor T Cell Therapy for B
Lymphoblastic Leukemia
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell
Lymphoma, Chronic Lymphocytic Leukemia
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of
Bispecific Antibodies
The Future of Chimeric Antigen Receptor T Cell Therapy